Evidence map›Paper›PMID 42308036›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

Dynamic monitoring of antibody drug conjugates targeting TROP2 or HER2 in breast cancer using circulating tumor cells.

Avanish Mishra, Rachel O Abelman, Quinn Cunneely, Victor Putaturo, Akansha A Deshpande, Remy Bell, Elizabeth M Seider, Katherine H Xu, Mythreayi Shan, Justin Kelly and 15 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Avanish Mishra *Center for Engineering in Medicine and Surgery, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129.
Rachel O Abelman *Division of Hematology Oncology, Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA 02114.
Quinn Cunneely *Center for Engineering in Medicine and Surgery, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129.
Victor PutaturoCenter for Engineering in Medicine and Surgery, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129.
Akansha A DeshpandeCenter for Engineering in Medicine and Surgery, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129.
Remy BellCenter for Engineering in Medicine and Surgery, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129.
Elizabeth M SeiderKrantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA 02129.
Katherine H XuKrantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA 02129.
Mythreayi ShanKrantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA 02129.
Justin KellyKrantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA 02129.
Shih-Bo HuangKrantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA 02129.
Olivia RieurDivision of Hematology Oncology, Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA 02114.
Justine KnapeDivision of Hematology Oncology, Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA 02114.
Kaustav A GopinathanCenter for Engineering in Medicine and Surgery, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129.
Kruthika KikkeriCenter for Engineering in Medicine and Surgery, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129.
Jon F EddCenter for Engineering in Medicine and Surgery, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129.
John WalshCenter for Engineering in Medicine and Surgery, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129.
Charles S DaiKrantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA 02129.
Leif W EllisenKrantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA 02129.ORCID 0000-0003-0444-7910
David T TingKrantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA 02129.ORCID 0000-0002-3261-2322
Linda NiemanKrantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA 02129.
Mehmet TonerCenter for Engineering in Medicine and Surgery, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129.
Aditya BardiaDivision of Hematology Oncology, Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA 02114.
Daniel A HaberKrantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA 02129.ORCID 0000-0003-1378-6551
Shyamala MaheswaranKrantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, MA 02129.

Funding

High-flow microfluidics of leukapheresis blood products for functional analysis of breast circulating tumor cellsR01CA255602 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HABER, DANIEL A., MAHESWARAN, SHYAMALA · 2021 to 2025
$3.2M
Precision Apheresis: stem cell isolation from patients with sickle cell disease for gene therapy using high-throughput microfluidicsK25HL169816 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI Avanish Mishra · 2023 to 2026
$550k
Breast Cancer Research Foundation (BCRF) NAHHS | NIH | National Cancer Institute (NCI) 129933HHS | NIH | National Cancer Institute (NCI) 169816HHS | NIH | National Cancer Institute (NCI) 214297HHS | NIH | National Cancer Institute (NCI) 255602HHS | NIH | National Cancer Institute (NCI) 260989Howard Hughes Medical Institute (HHMI) NANational Foundation for Cancer Research (NFCR) NANCI NIH HHS R01 CA255602NHLBI NIH HHS K25 HL169816
6 · The paper itself

Abstract

Antibody-drug conjugates (ADCs) target surface proteins on cancer cells, leading to internalization and delivery of a drug payload, thereby enhancing selectivity and minimizing toxicity. ADCs against TROP2 (Sacituzumab govitecan) or HER2 (T-DXd) have demonstrated efficacy in metastatic breast cancer, yet paradoxically, outside of

Indexed as

Antibodies, Monoclonal, HumanizedAntigens, NeoplasmBreast NeoplasmsCell Adhesion MoleculesErb-b2 Receptor Tyrosine KinasesImmunoconjugatesNeoplastic Cells, CirculatingCamptothecinFemaleHumansProspective StudiesAntibodies, Monoclonal, HumanizedAntigens, NeoplasmCamptothecinCell Adhesion MoleculesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmunoconjugatessacituzumab govitecanTACSTD2 protein, humanantibody-drug-conjugatebreast cancercirculating tumor cellsHER2TROP2

Identifiers

PMID42308036
PMCPMC13291658

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.